Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories

ARUP to commercialize laboratory-developed blood test based on
Epigenomics' mSEPT9 biomarker to aid in the early detection of 
colorectal
 cancer
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
companies/cooperations/Molecular diagnostics
Press Release, Berlin, Germany and Seattle, WA, U.S.A., August 12, 
2009 (euro adhoc) - Epigenomics AG (Frankfurt, Prime Standard: ECX), 
a cancer molecular diagnostics company, today announced that it 
signed a non-exclusive licensing agreement for its proprietary DNA 
methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah, 
U.S. based ARUP Laboratories, Inc. (ARUP), a leading provider of 
diagnostic testing services. Under the agreement, ARUP has obtained 
rights to use the mSEPT9 biomarker to develop a molecular-based 
laboratory test that can help physicians detect colorectal cancer 
based on a patient's blood sample. Colorectal cancer is the second 
leading cause of cancer-related deaths in the U.S. Epigenomics has 
repeatedly demonstrated that methylated DNA of the Septin 9 gene in 
blood plasma indicates the presence of colorectal cancer in early 
stages.
"Having a simple blood test that can detect colorectal cancer will be
a major step in the fight against this dreadful disease, which is 
often curable when caught in the early stages," said Ronald L. Weiss,
MD, MBA, ARUP Executive Vice President of Health Policy, External 
Affairs, and Corporate Communication. "Patient compliance in the U.S 
with current colorectal cancer screening guidelines leaves a lot to 
be desired. All too often, patients fail to undergo a colonoscopy or 
conduct other types of colorectal cancer screenings because they find
these methods invasive, unpleasant or costly. A blood test for 
detecting colorectal cancer, will be a convenient option that 
complements other screening methods."
ARUP (www.aruplab.com) is the second commercial laboratory in the 
U.S.A. to non- exclusively license the mSEPT9 biomarker from 
Epigenomics with the goal of commercializing a laboratory-developed 
blood test.
"ARUP is an ideal second laboratory partner to use our mSEPT9 
biomarker technology to commercialize a laboratory-developed test for
detecting colorectal cancer," said Geert Nygaard, Chief Executive 
Officer of Epigenomics AG. "We selected ARUP because they have a 
record of innovation in molecular diagnostics. They also share our 
objective of developing tests that will help physicians to improve 
the health outcomes for their patients through accurate detection of 
early-stage colorectal cancer. With today's licensing agreement we 
continue to execute on our non-exclusive commercialization strategy 
for our colorectal cancer biomarker. The agreement with ARUP for the 
commercialization of a laboratory-developed test for mSEPT9 
complements our current agreements with Quest Diagnostics for an 
mSEPT9-based laboratory developed test, Abbott Molecular, who 
obtained the non-exclusive rights to commercialize IVD test kit 
products based on mSEPT9, as well as Sysmex" explained Mr. Nygaard.
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the 
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests in development aim at diagnosing 
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease. Epigenomics' product pipeline 
contains a validated biomarker for the early detection of colorectal 
cancer in blood plasma, and further proprietary DNA methylation 
biomarkers at various stages of development for prostate and lung 
cancer detection in urine, blood and bronchial lavage specimens. 
Epigenomics' biomarker mSEPT9 for the early detection of colorectal 
cancer in a simple blood sample has demonstrated continuously highest
performance in multiple clinical studies with in total more than 
3,500 individuals tested. A large prospective clinical study - 
PRESEPT - for evaluation of mSEPT9 in a screening population is 
currently under way (www.presept.net).
For development and global commercialization of in vitro diagnostic 
test products, Epigenomics pursues a non-exclusive partnering 
strategy. Strategic diagnostics industry partners include Abbott 
Molecular, Philips, Sysmex Corporation, Quest Diagnostics 
Incorporated, and ARUP Laboratories, Inc. for diagnostics test 
products and services, and QIAGEN N.V. for sample preparation 
solutions and research products.
Partners in the health care industry and the biomedical research 
community can access Epigenomics' portfolio of proprietary DNA 
methylation technologies and biomarkers protected by more than 150 
patent families through research products, Biomarker Services, IVD 
Development Collaborations, and Licensing. The company is 
headquartered in Berlin, Germany, and has a wholly owned subsidiary 
in Seattle, WA, U.S.A. For more information, please visit 
Epigenomics' website at www.epigenomics.com.
Epigenomics legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale in the 
United States. The analytical and clinical performance 
characteristics of any product based on this technology which may be 
sold at some future time in the U.S. have not been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG
  • 11.08.2009 – 08:32

    EANS-News: Epigenomics AG Reports First Half 2009 Results

    Key Figures . Revenue: EUR 2.1 million in H1 2009, up by 37% (H1 2008: EUR 1.5 million) . EBIT: EUR - 4.8 million in H1 2009, improved by 19% (H1 2008: EUR -5.9 million) . Net loss: EUR - 4.8 million in H1 2009, decreased by 15% (H1 2008: EUR -5.6 illion) . Liquid assets: EUR 12.1 million as of 30/06/2009 (31/12/2008: EUR 12.1 million) Highlights of the First Half 2009 . Significantly improved ...

  • 20.07.2009 – 10:01

    EANS-News: DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics

    Both companies to use Scorpions® technology for diagnostic products based on DNA methylation Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/cooperations/Molecular diagnostics Press Release, Manchester, UK, and Berlin, Germany, July 20, 2009 (euro adhoc) - DxS Ltd. ...

  • 30.06.2009 – 10:01

    EANS-News: Epigenomics AG Certified for Diagnostic Product Development and Commercialization

    ISO 13485 certification marks a milestone in Epigenomics' commercial strategy Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. companies/new product/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, June 30, 2009 (euro adhoc) - Epigenomics AG (Frankfurt Prime ...